, Tracking Stock Market Picks
Enter Symbol:
Echo Therapeutics (ECTE) [hlAlert]

down 89.72 %

Echo Therapeutics (ECTE) rated Buy with price target $2 by Ascendiant Capital Markets

Posted on: Monday,  Aug 6, 2012  6:56 PM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Buy Echo Therapeutics (NASDAQ: ECTE) on 08/06/2012, when the stock price was $14.50. Since
then, Echo Therapeutics has lost 89.72% as of 01/26/2016's recent price of $1.49.
If you would have followed this Ascendiant Capital Markets's recommendation on ECTE, you would have lost 89.72% of your investment in 1268 days.

Echo Therapeutics, Inc. (Echo) is a medical device and specialty pharmaceutical company. The Company is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes together with a range of transdermal reformulations of specialty pharmaceutical products approved by the United States Food and Drug Administration (FDA). The Symphony tCGM System is a non-invasive (needle-free), wireless tCGM system designed to provide blood glucose data. Symphony incorporates the feedback mechanism for optimal skin permeation control and the transdermal sensor to detect glucose trends, for controlling complications associated with blood glucose levels that stray outside of a target range. Symphony incorporates the skin permeation, transdermal sensor, wireless transmission and data display technologies. The specialty pharmaceuticals pipeline is based on the AzoneTS transdermal drug reformulation technology.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2012 6:56 PM Buy
14.50 20.00
as of 12/31/2012
1 Week up  5.05 %
1 Month down  -13.33 %
3 Months down  -33.75 %
1 YTD down  -28.27 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy